Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor

Metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK+), ROS1 gene rearrangements (ROS1+), or epidermal growth factor receptor mutations (EGFR-MTs) have high response rates and long progression free survival (PFS) when treated with the appropriate first or next-generation tyrosine kinase inhibitor (TKI) [1 –6]. However, progression usually occurs due to inadequate central nervous system (CNS) penetration of the drug leading to CNS-only progression, the development of new kinase domain mutations, or the development of alternate oncogenic drivers [7–16].

Source: Lung Cancer - October 22, 2018 Category: Cancer & Oncology Authors: Terry L. Ng, Rustain L. Morgan, Tejas Patil, Anna E. Bar ón, Derek E. Smith, D. Ross Camidge Source Type: research